CN107250349A - 多能干细胞的悬浮培养 - Google Patents

多能干细胞的悬浮培养 Download PDF

Info

Publication number
CN107250349A
CN107250349A CN201580076646.0A CN201580076646A CN107250349A CN 107250349 A CN107250349 A CN 107250349A CN 201580076646 A CN201580076646 A CN 201580076646A CN 107250349 A CN107250349 A CN 107250349A
Authority
CN
China
Prior art keywords
cell
stage
day
culture
culture medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580076646.0A
Other languages
English (en)
Chinese (zh)
Inventor
B.弗耶
D.拉尼奥斯卡斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Centocor Ortho Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Ortho Biotech Inc filed Critical Centocor Ortho Biotech Inc
Publication of CN107250349A publication Critical patent/CN107250349A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/117—Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/19—Growth and differentiation factors [GDF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/395—Thyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C12N2501/91—Heparin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201580076646.0A 2014-12-19 2015-12-09 多能干细胞的悬浮培养 Pending CN107250349A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462094509P 2014-12-19 2014-12-19
US62/094,509 2014-12-19
PCT/US2015/064713 WO2016100035A1 (en) 2014-12-19 2015-12-09 Suspension culturing of pluripotent stem cells

Publications (1)

Publication Number Publication Date
CN107250349A true CN107250349A (zh) 2017-10-13

Family

ID=56127372

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580076646.0A Pending CN107250349A (zh) 2014-12-19 2015-12-09 多能干细胞的悬浮培养

Country Status (16)

Country Link
US (1) US20160215268A1 (cg-RX-API-DMAC7.html)
EP (1) EP3234109A4 (cg-RX-API-DMAC7.html)
JP (1) JP6800854B2 (cg-RX-API-DMAC7.html)
KR (3) KR102700499B1 (cg-RX-API-DMAC7.html)
CN (1) CN107250349A (cg-RX-API-DMAC7.html)
AR (1) AR103080A1 (cg-RX-API-DMAC7.html)
AU (1) AU2015363008B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017012974A2 (cg-RX-API-DMAC7.html)
CA (1) CA2970935A1 (cg-RX-API-DMAC7.html)
MX (1) MX2017008176A (cg-RX-API-DMAC7.html)
PH (1) PH12017501153A1 (cg-RX-API-DMAC7.html)
RU (1) RU2017125728A (cg-RX-API-DMAC7.html)
SG (1) SG11201704961VA (cg-RX-API-DMAC7.html)
TW (1) TW201636421A (cg-RX-API-DMAC7.html)
WO (1) WO2016100035A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201704868B (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112867787A (zh) * 2018-09-19 2021-05-28 武田药品工业株式会社 胰岛素产生细胞
CN119432595A (zh) * 2023-08-07 2025-02-14 浙江霍德生物工程有限公司 利用生物反应器进行诱导多能干细胞的悬浮培养

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3012603A1 (en) 2016-01-26 2017-08-03 Centre For Commercialization Of Regenerative Medicine Method for dissociating cell aggregates
US10391156B2 (en) 2017-07-12 2019-08-27 Viacyte, Inc. University donor cells and related methods
JP2020527956A (ja) * 2017-07-21 2020-09-17 センマ・セラピューティクス・インコーポレーテッド 幹細胞由来の膵臓ベータ細胞の再凝集
SG11202001906PA (en) * 2017-09-11 2020-04-29 Novo Nordisk As Enrichment of nkx6.1 and c-peptide co-expressing cells derived in vitro from stem cells
WO2019099725A1 (en) * 2017-11-15 2019-05-23 Semma Therapeutics, Inc. Islet cell manufacturing compositions and methods of use
WO2019169351A1 (en) 2018-03-02 2019-09-06 Semma Therapeutics, Inc. Methods of enhancing stem cell differentiation into beta cells
EP3833365A4 (en) 2018-08-10 2022-05-11 Vertex Pharmaceuticals Incorporated Stem cell derived islet differentiation
US12378572B2 (en) 2018-09-07 2025-08-05 Crispr Therapeutics Ag Universal donor cells
EP3953451A1 (en) * 2019-04-08 2022-02-16 Novo Nordisk A/S Generation of pancreatic endoderm from stem cell derived definitive endoderm
AU2020282355B2 (en) 2019-05-31 2023-11-02 Viacyte, Inc. A biocompatible membrane composite
CA3257300A1 (en) 2019-05-31 2025-06-12 W. L. Gore & Associates, Inc. Cell encapsulation devices with controlled oxygen diffusion distances
EP3975926A1 (en) 2019-05-31 2022-04-06 W.L. Gore & Associates, Inc. A biocompatible membrane composite
US12310830B2 (en) 2019-05-31 2025-05-27 W. L. Gore & Associates, Inc. Biocompatible membrane composite
US11104918B2 (en) 2019-09-05 2021-08-31 Crispr Therapeutics Ag Universal donor cells
US11116798B2 (en) 2019-09-05 2021-09-14 Crispr Therapeutics Ag Universal donor cells
US11566230B2 (en) 2020-12-31 2023-01-31 Crispr Therapeutics Ag Universal donor cells
IL328729A (en) * 2023-12-01 2026-07-01 Sigilon Therapeutics Inc Methods for producing stem cell-derived islet-like cells, as well as populations and compositions comprising them

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050266554A1 (en) * 2004-04-27 2005-12-01 D Amour Kevin A PDX1 expressing endoderm
WO2007103282A2 (en) * 2006-03-02 2007-09-13 Cythera, Inc. Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production
WO2011139628A1 (en) * 2010-04-25 2011-11-10 Mount Sinai School Of Medicine Generation of anterior foregut endoderm from pluripotent cells
US20110280842A1 (en) * 2008-08-22 2011-11-17 Presidents And Fellows Of Harvard College Methods of reprogramming cells
US20130189777A1 (en) * 2011-12-22 2013-07-25 Janssen Biotech, Inc. Differentiation of Human Embryonic Stem Cells into Single Hormonal Insulin Positive Cells

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
GB2399823B (en) 2001-12-07 2006-02-15 Geron Corp Islet cells from primate pluripotent stem cells
ES2569780T3 (es) 2003-06-27 2016-05-12 DePuy Synthes Products, Inc. Células posparto derivadas de tejido placentario y métodos de preparación y uso de las mismas
EP2722387B1 (en) 2003-12-23 2019-12-11 Viacyte, Inc. Definitive endoderm
SG150567A1 (en) 2004-03-23 2009-03-30 Akaike Toshihiro Pluripotent stem cell growing method
EP1853698A1 (en) 2005-01-28 2007-11-14 NovaThera Ltd. Methods for embryonic stem cell culture
AU2006202209B2 (en) 2005-05-27 2011-04-14 Lifescan, Inc. Amniotic fluid derived cells
WO2007026353A2 (en) 2005-08-29 2007-03-08 Technion Research & Development Foundation Ltd. Media for culturing stem cells
ES2687233T3 (es) * 2005-10-27 2018-10-24 Viacyte, Inc. Endodermo de intestino proximal dorsal y ventral que expresa PDX-1
US7695965B2 (en) 2006-03-02 2010-04-13 Cythera, Inc. Methods of producing pancreatic hormones
WO2008013664A2 (en) 2006-07-26 2008-01-31 Cythera, Inc. Methods of producing pancreatic hormones
DK2733203T3 (en) 2006-08-02 2019-02-04 Technion Res & Dev Foundation PROCEDURES FOR EXPANSION OF EMBRYONAL STEM CELLS IN A SUSPENSION CULTURE
AU2008272949B2 (en) 2007-06-29 2014-05-15 FUJIFILM Cellular Dynamics, Inc. Automated method and apparatus for embryonic stem cell culture
CA2729121C (en) * 2008-06-30 2019-04-09 Centocor Ortho Biotech Inc. Differentiation of pluripotent stem cells
PH12012500818A1 (en) 2009-10-29 2019-11-29 Janssen Biotech Inc Pluripotent stem cells
MX2015008578A (es) * 2012-12-31 2015-09-07 Janssen Biotech Inc Diferenciacion de celulas madre embrionarias humanas en celulas endocrinas pancreaticas mediante el uso de relugadores de hb9.
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050266554A1 (en) * 2004-04-27 2005-12-01 D Amour Kevin A PDX1 expressing endoderm
WO2007103282A2 (en) * 2006-03-02 2007-09-13 Cythera, Inc. Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production
US20110280842A1 (en) * 2008-08-22 2011-11-17 Presidents And Fellows Of Harvard College Methods of reprogramming cells
WO2011139628A1 (en) * 2010-04-25 2011-11-10 Mount Sinai School Of Medicine Generation of anterior foregut endoderm from pluripotent cells
US20130189777A1 (en) * 2011-12-22 2013-07-25 Janssen Biotech, Inc. Differentiation of Human Embryonic Stem Cells into Single Hormonal Insulin Positive Cells

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KEVIN A D"AMOUR ET AL.,: "Production of pancreatic hormone expressing endocrine cells from human embryonic stem cells", 《NATURE BIOTECHNOLOGY》 *
RACHEL E. JENNINGS ET AL.,: "Development of the Human Pancreas From Foregut to Endocrine Commitment", 《DIABETES》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112867787A (zh) * 2018-09-19 2021-05-28 武田药品工业株式会社 胰岛素产生细胞
CN119432595A (zh) * 2023-08-07 2025-02-14 浙江霍德生物工程有限公司 利用生物反应器进行诱导多能干细胞的悬浮培养

Also Published As

Publication number Publication date
KR20230050478A (ko) 2023-04-14
EP3234109A4 (en) 2018-06-27
AU2015363008B2 (en) 2021-12-09
KR20210094141A (ko) 2021-07-28
BR112017012974A2 (pt) 2018-01-09
KR102700499B1 (ko) 2024-08-28
KR20170087520A (ko) 2017-07-28
PH12017501153A1 (en) 2017-11-27
AR103080A1 (es) 2017-04-12
SG11201704961VA (en) 2017-07-28
MX2017008176A (es) 2018-02-09
CA2970935A1 (en) 2016-06-23
JP2017537649A (ja) 2017-12-21
JP6800854B2 (ja) 2020-12-16
KR102519502B1 (ko) 2023-04-06
RU2017125728A3 (cg-RX-API-DMAC7.html) 2019-06-03
EP3234109A1 (en) 2017-10-25
US20160215268A1 (en) 2016-07-28
AU2015363008A1 (en) 2017-06-29
RU2017125728A (ru) 2019-01-22
WO2016100035A1 (en) 2016-06-23
TW201636421A (zh) 2016-10-16
ZA201704868B (en) 2019-02-27
KR102281752B1 (ko) 2021-07-23

Similar Documents

Publication Publication Date Title
KR102519502B1 (ko) 만능성 줄기 세포의 현탁 배양
US10377989B2 (en) Methods for suspension cultures of human pluripotent stem cells
RU2689710C2 (ru) Суспендирование и кластеризация плюрипотентных стволовых клеток человека с целью их дифференцировки в панкреатические эндокринные клетки
US10370644B2 (en) Method for making human pluripotent suspension cultures and cells derived therefrom
AU2014248167B2 (en) Methods and compositions for culturing endoderm progenitor cells in suspension

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination